Dengue Efficacy Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Get latest articles and stories on Business at LatestLY. Singapore, February 27: Takeda (TSE:4502/NYSE:TAK) today announced a strategic partnership with Biological E. Limited, a leading vaccines and biologics company in India, to manufacture Takeda's dengue vaccine, TAK-003. The partnership marks a crucial step in the fight against the global public health threat of dengue fever, aligning with the disease-specific target set by the World Health Organization (WHO) to achieve zero case-fatality rate due to dengue by 2030[i]. Business News | Takeda Accelerates Access to Its Dengue Vacci...

Takeda today announced that the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization shared recommendations for use of QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003).

Experts Reviewed Data from QDENGA’s Clinical Program Across 19 Phase 1, 2 and 3 Trials with More Than 28,000 ParticipantsWHO Will Consider the SAGE Recommendation and Provide Final Guidance on the Use of QDENGA in Public Vaccination Programs in the Coming MonthsDengue Poses a Significant and Growing Public Health Bu...

Takeda TSE4502NYSETAK today announced that the World Health Organizations WHO Strategic Advisory Group of Experts SAGE on Immunization shared recommendations for use of QDENGA Dengue Tetravalent Vaccine Live Attenuated TAK003.

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 3, 2023--